FLC | Three HHS agencies launch COVID-19 SeroHub to track seroprevalance

Three HHS agencies launch COVID-19 SeroHub to track seroprevalance

December 1, 2020

A collaboration among the National Institute of Allergy and Infectious Diseases, the Centers for Disease Control and Prevention, and the National Cancer Institute (NCI) has developed the COVID-19 Seroprevalence Hub (COVID-19 SeroHub), a central repository of SARS-CoV-2 seroprevalence studies.

The SeroHub is an online dashboard intended to help researchers and policymakers monitor studies of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) seroprevalence in the United States. These studies use blood tests to identify the proportion of people in the population who possess antibodies to SARS-CoV-2 as an indication of prior infection. Seroprevalence data show how the virus is spreading within the U.S. population, enabling scientists and policymakers to better understand who is most at risk for disease, as well as who might be protected from infection.

Using COVID-19 SeroHub, researchers can track studies conducted by various contributors at the national, state, and local levels on the seroprevalence of SARS-Cov-2 throughout the United States. The interactive dashboard allows scientists to visualize and compare SARS-Cov-2 seroprevalence rates by geography, dates of testing, and population descriptors.

The COVID-19 SeroHub is still in development. Studies included to date have been identified via literature search and review of National Institutes of Health portfolios. Information from each identified study has been extracted using a common set of data fields. In the near future, the SeroHub's developers plan to release additional tools to visually display these data and sort by key fields such as date of sample collection, geographic area, and study population.